Successes and challenges of insulin therapy for type 2 diabetes in a managed-care setting

References

• UKPDS Group. Glycemic control with diet, sulphonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies UKPDS 49. JAMA 1999;281:2005-12
   PubMed Web of Science ®Google Scholar
• De Witt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: a scientific review. JAMA 2003;289:2254-64
   PubMed Web of Science ®Google Scholar
• Dailey GE III. Early insulin: an important therapeutic strategy. Diabetes Care 2005;28:220-1
   PubMed Web of Science ®Google Scholar
• Meneghini L. Why and how to use insulin therapy earlier in the management of type 2 diabetes. South Med J 2007;100:164-74
   PubMed Web of Science ®Google Scholar
• Davidson MB. Early insulin therapy for type 2 diabetic patients: more cost than benefit. Diabetes Care 2005;28:222-4
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32:193-203
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005;28:2543-5
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673-9
   PubMed Web of Science ®Google Scholar
• Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004;27:1535-40
   PubMed Web of Science ®Google Scholar
• Nichols GA, Koo YH, Shah SN. Delay of insulin addition to oral combination therapy despite inadequate glycemic control. J Gen Intern Med 2007;22:453-8
   PubMed Web of Science ®Google Scholar
• van Avendonk MJ, Rutten GE. Insulin therapy in type 2 diabetes: what is the evidence? Diabetes Obes Metab 2009; epub ahead of print
   Google Scholar
• Hirsch IB, Bergenstal RM, Parkin CG, et al. A real-world approach to insulin therapy in primary care practice. Clin Diabetes 2005;23:78-86
   Google Scholar
• Tibaldi J. Initiating and intensifying insulin therapy in type 2 diabetes mellitus. Am J Med 2008;121:S20-9
   PubMed Web of Science ®Google Scholar
• Vinik A. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy. Clin Ther 2007;29:1236-53
   Web of Science ®Google Scholar
• Horton ES. Defining the role of basal and prandial insulin for optimal glycemic control. J Am Coll Cardiol 2009;53:S21-7
   PubMed Web of Science ®Google Scholar
• Spellman CW. Insulin therapy for maximal glycemic control in type 2 diabetes mellitus. J Am Osteopath Assoc 2007;107:260-9
   PubMedGoogle Scholar
• Alexander GC, Sehgal NL, Moloney RM, et al. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med 2008;168:2088-94
   PubMed Web of Science ®Google Scholar
• Brown JB, Nichols GA, Glauber HS. Case-control study of 10 years of comprehensive diabetes care. West J Med 2000;172:85-90
   PubMedGoogle Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29:1963-72
   PubMed Web of Science ®Google Scholar
• CDC Diabetes Cost-Effectiveness Study Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002;287:2542-51
   PubMed Web of Science ®Google Scholar
• Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-30
   PubMed Web of Science ®Google Scholar
• Miller CD, Phillips LS, Ziemer DC, et al. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001;161:1653-9
   PubMed Web of Science ®Google Scholar
• Akram K, Pedersen-Bjergaard U, Borch-Johnsen K, et al. Frequency and risk factors of severe hypoglycemia in insulin-treated type 2 diabetes: a literature survey. J Diabetes Complications 2006;20:402-8
   PubMed Web of Science ®Google Scholar
• Nichols GA, Gomez-Caminero A. Weight changes following the initiation of new anti-hyperglycemic therapies. Diabetes Obes Metab 2007;9:96-102
   PubMed Web of Science ®Google Scholar
• UKPDS Group. UKPDS 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998;128:165-75
   PubMed Web of Science ®Google Scholar
• The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
   PubMed Web of Science ®Google Scholar
• The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39
   PubMed Web of Science ®Google Scholar